Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance

-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.701 ---- Reflects strength of Eagle's business and product pipeline;